Could a common diabetes drug protect hearts in kidney failure?
NCT ID NCT06182839
First seen Jan 06, 2026 · Last updated May 20, 2026 · Updated 29 times
Summary
This study tests whether canagliflozin, a drug used for diabetes, can improve heart structure and function in people with advanced kidney disease, including those on dialysis. About 92 participants will receive either the drug or a placebo, and heart changes will be measured using MRI scans over 12 months. The goal is to see if the drug can reduce heart damage common in this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESRD, CKD STAGE 4, CKD STAGE 5 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Center
RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.